News

Veru Inc.'s Keynote at World Obesity Congress: Enobosarm Benefits

Veru Inc.'s Keynote at World Obesity Congress: Enobosarm Benefits

Veru Inc. to Present on Enobosarm's Role in Weight Loss

Veru Inc. (NASDAQ: VERU), a biopharmaceutical leader dedicated to advancing healthcare solutions, is gearing up to deliver a keynote presentation at the World Obesity and Weight Management Congress. Expected to capture attention, this event will occur in late October, where Veru will delve into the innovative use of enobosarm, a selective androgen receptor modulator (SARM), in tandem with GLP-1 receptor agonists.

Key Details of the Presentation

The presentation will focus on how enobosarm can effectively prevent muscle loss while augmenting fat reduction, potentially leading to higher quality weight loss. The session is scheduled for October 25, 2024, from 9:40 AM to 10:20 AM Eastern Time, hosted at the Best Western Plus Hotel & Conference Center. Veru is excited to engage with healthcare professionals to discuss the implications of their research.

Understanding the Research and Trials

The Phase 2b clinical trial for enobosarm is currently in progress, evaluating 168 patients struggling with sarcopenic obesity. The trial aims to assess both safety and efficacy, focusing specifically on the preservation of lean muscle mass and fat loss. By combining enobosarm with semaglutide, participants might experience greater benefits in their weight management journeys.

Details on the Phase 2b Study

In this rigorous study, patients aged over 60 will be randomized to receive either enobosarm doses or a placebo. The main goal is to determine the impact on total lean body mass after an extensive monitoring period of 16 weeks. The study also encompasses secondary goals to measure overall body fat and physical function using various tests, including assessing stair-climbing ability.

The Significance of Sarcopenic Obesity

The increasing prevalence of obesity among older adults highlights the need for targeted treatments. Research indicates that a significant portion of older adults are affected by sarcopenic obesity, which poses serious health risks. Patients in this category often struggle with muscle weakness and mobility challenges, exacerbating their health issues.

Addressing the Risks

Given that GLP-1 receptor agonists may lead to further muscle loss, the combination therapy with enobosarm might provide a protective effect. By addressing muscle preservation, Veru aims to mitigate the dangers associated with frailty in older patients, creating opportunities for improved health outcomes.

Enobosarm: The Innovative Solution

Enobosarm has shown promise in previous clinical studies, demonstrating its ability to increase muscle mass and reduce fat effectively. These outcomes are essential for patients with underlying conditions, including advanced cancer, which often leads to muscle wasting and significant weight loss.

Clinical Insights and Future Directions

As clinical trials progress, Veru Inc. collects valuable data that reinforces the role of enobosarm as a leading contender in treating muscle loss. Additionally, it boasts a robust safety profile, indicating minimal side effects, which is particularly beneficial when used alongside other weight-loss medications that might introduce gastrointestinal challenges.

About Veru Inc.

Established as a frontrunner in biopharmaceutical innovation, Veru Inc. is dedicated to developing advanced treatments targeting metabolic diseases, cancer, and respiratory conditions. Their current pipeline not only features enobosarm but also sabizabulin, aimed at treating patients experiencing severe respiratory distress due to viral infections.

Frequently Asked Questions

What is the focus of Veru's keynote presentation?

The presentation focuses on the scientific support for enobosarm in combination with GLP-1 receptor agonists to preserve muscle for effective weight loss.

When will the presentation take place?

The keynote is scheduled for October 25, 2024, from 9:40 AM to 10:20 AM Eastern Time.

What is the main aim of the Phase 2b clinical trial?

It aims to evaluate the safety and efficacy of enobosarm in preserving muscle while promoting fat loss in older patients with sarcopenic obesity.

How does enobosarm work?

Enobosarm is a selective androgen receptor modulator that helps increase muscle mass while supporting fat reduction, addressing issues related to muscle loss in older adults.

What conditions is Veru targeting with its treatments?

Veru targets conditions including sarcopenic obesity, cancer-related weight loss, and respiratory distress syndrome caused by viral infections.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Boston Scientific Loads Debt Cannon for Penumbra Deal

Updated Category News Views 128

A Very Large Financing Cart Rolled Out Boston Scientific just put an enormous stack of paper into the market, and nobody should mistake this for routine housekeeping. The company priced $3.0 billion of U.S. dollar senior notes and €4.25 billion of euro notes, with proceeds earmarked chiefly for the cash portion of its proposed Penumbra acquisition, alongside cash on...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 93

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 50

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 80

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 87

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 138

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 0

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 96

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Bill Targets 15% Federal Goal for Women-Owned Firms

Updated Category News Views 51

Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $1000 into $3500: The Cboe Investment Journey

Updated Category News Views 346

A Decade of Growth: The Journey of Cboe Global Markets Cboe Global Markets (NASDAQ: CBOE) has showcased remarkable performance over the last ten years. With an average annual return of 13.08%, the stock has consistently outpaced the market by 1.88%. As of now, the company boasts a significant market capitalization of $22.24 billion, reflecting its robust position in the...

Continue Reading
New Jersey's Hemp Law Blocked by Judge: A Look into the Future

Updated Category News Views 227

New Jersey's Hemp Law Blocked by Judge: A Look into the Future A recent court ruling has caused a significant shift in New Jersey’s hemp regulation landscape. A federal judge has ruled parts of the Revised New Jersey Hemp Law unconstitutional, asserting that certain provisions unfairly restrict interstate commerce and counter federal guidelines. This decision marks a...

Continue Reading
Kirkland's Fights Through Challenges with Strategic Plans

Updated Category News Views 175

Kirkland's Reports Mixed Results for Q2 Amid Strategic Changes Kirkland's (NASDAQ: KIRK), a well-known specialty retailer specializing in home décor and gifts, has released its financial results for the second quarter. The company experienced a 1.7% decline in total comparable sales, largely driven by a significant 10.6% drop in e-commerce sales. On a more positive note,...

Continue Reading
noco-noco Inc Updates Timeline for Share Consolidation Strategy

Updated Category News Views 89

noco-noco Inc Announces New Timeline for Reverse Stock Split Recently, noco-noco Inc. has made significant updates regarding its plans for a reverse stock split, a necessary step to align with Nasdaq’s minimum bid price requirement. This decision follows an unforeseen delay that would impede their initial plan set for implementation. Background on the Reverse Stock...

Continue Reading
Strong Performance of Mexican Stocks Fuels Investor Confidence

Updated Category News Views 187

Mexican Stock Market Sees Positive Gains Recently, investors in the Mexican stock market experienced an uplift as stocks showed significant gains. The market closed higher, indicating a robust performance across various sectors. This surge was primarily driven by strong performances in key areas such as Industrials, Consumer Goods, and Consumer Staples, all contributing...

Continue Reading